Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers.
Kent C. Shih
Research Funding - Celgene
Johanna C. Bendell
Research Funding - Celgene
Anne Reinert
Research Funding - Celgene
Suzanne Jones
Research Funding - Celgene
Robin Katie Kelley
Research Funding - Celgene
Jeffrey R. Infante
Research Funding - Celgene
Michael Korn
Research Funding - Celgene
Kristen Hege
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Rajesh Chopra
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Shuichan Xu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Lilly Wong
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Yong Liu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Deborah Mortensen
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Pamela N. Munster
Research Funding - Celgene